Oryzon Genomics S.A. (BME:ORY)
2.810
-0.050 (-1.75%)
At close: Mar 18, 2026
Oryzon Genomics Employees
Oryzon Genomics had 47 employees as of June 30, 2025. The number of employees did not change since the number was reported on December 31, 2024.
Employees
47
Change
n/a
Growth
n/a
Revenue / Employee
€232,648
Profits / Employee
€55,436
Market Cap
217.81M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 47 | 0 | - |
| Dec 31, 2024 | 47 | 1 | 2.17% |
| Dec 31, 2023 | 46 | 2 | 4.78% |
| Dec 31, 2022 | 44 | 0 | - |
| Dec 31, 2021 | 44 | 1 | 1.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Grifols | 25,258 |
| Almirall | 2,108 |
| Laboratorios Farmaceuticos Rovi | 2,045 |
| Atrys Health | 2,016 |
| Clínica Baviera | 1,847 |
| Laboratorio Reig Jofre | 1,426 |
| Prim, S.A. | 902 |
| Pharma Mar | 500 |
Oryzon Genomics News
- 22 days ago - ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia - Benzinga